Running throughout the 23rd, 24th and 25th January
Phacilitate:Talks is a brand new addition to the Phacilitate Leaders World exhibition. A carefully curated stage will share the stories behind the successes and struggles in advanced therapies – and it’s open to all.
We believe that some of the most interesting stories in this industry aren’t to be found in data sets and product launches, but rather in the stories behind them. Phacilitate:Talks is a new stage with no PowerPoints, no fuss, just brilliant storytelling.
The sessions are grouped according to 3 main themes. It’s going to be an adventure, and you’re not going to want to miss it.
The beauty and the curse of being first
From being first to market to being the first to describe a breakthrough, the first to sit on the board or the first to fail – being first can be an advantage, but it can be a double-edged sword, providing boundless opportunities and plenty of hurdles along the way!
- Federico Mingozzi, CSO, Spark Therapeutics on launching the first gene therapy to market and the importance of cross-stakeholder synergies
- Dwayne Soisson, Senior Director, Operations, Dendreon on the launch of Provenge and Dendreon’s return from the brink of bankruptcy.
The power of seconds
This session is all about the power of seconds – second chances, second attempts, and being second to market. Sometimes what you really need is to take a step-back and look at things a little differently – so how can you change your view and come back tougher than ever?
- Nicole Gularte, Patient Advocate, Fight for Cures on being treated with CAR-T twice.
- Pierluigi Paracchi, Co-Founder and CEO, Genenta on how to ask strangers for money and get it (especially when you’re second to market!)
Far beyond, the future of advanced therapies
With such a rapid pace of development, can we predict what the future of advanced therapies looks like? Is it orbiting round the planet or sat right in front of us, framed on our desks and waiting to be picked up?
- Jana Stoudemire, Chief Commercialization Officer, Space Tango on space as the next frontier for global pharma
- Neil Canavan, Scientific Advisor, Trout Group on how a collection of drawings might reveal the future for CAR-T